Vir Biotechnology, Inc. (VIR)
10.74
+0.53
(+5.19%)
USD |
NASDAQ |
Oct 20, 16:00
10.75
+0.01
(+0.09%)
After-Hours: 07:09
Vir Biotechnology Research and Development Expense (TTM) : 471.79M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 471.79M |
| March 31, 2026 | 425.05M |
| December 31, 2025 | 432.80M |
| September 30, 2025 | 428.92M |
| June 30, 2025 | 470.73M |
| March 31, 2025 | 483.98M |
| December 31, 2024 | 463.19M |
| September 30, 2024 | 471.07M |
| June 30, 2024 | 425.02M |
| March 31, 2024 | 494.27M |
| December 31, 2023 | 529.72M |
| September 30, 2023 | 593.40M |
| June 30, 2023 | 562.22M |
| March 31, 2023 | 508.60M |
| December 31, 2022 | 467.86M |
| Date | Value |
|---|---|
| September 30, 2022 | 441.46M |
| June 30, 2022 | 425.54M |
| March 31, 2022 | 397.55M |
| December 31, 2021 | 442.34M |
| September 30, 2021 | 401.28M |
| June 30, 2021 | 373.17M |
| March 31, 2021 | 365.09M |
| December 31, 2020 | 288.78M |
| September 30, 2020 | 251.13M |
| June 30, 2020 | 220.87M |
| March 31, 2020 | 172.15M |
| December 31, 2019 | 139.83M |
| September 30, 2019 | 112.80M |
| June 30, 2019 | 103.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.635B |
| Vaxcyte, Inc. | 1.033B |
| Caribou Biosciences, Inc. | 85.77M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |